2022 World-Class Speaker Faculty:
Speakers
Abhigyan Satyam
Assistant Professor
Harvard Medical School, Harvard University
Track A - Day 1 PM
2:30 pm | Targeted Inhibition of Intracellular Complement Activation to Control Tissue Injury
Andrea Tenner
Professor
University of California, Irvine
Axel Vater
Founder & Chief Scientific Officer
APTARION biotech AG
Day Two
Thursday, September 29 2022
2:00 pm | C5a Neutralization by Clinical-Stage AON-D21 Shows Promise in Animal Models from Pneumonia to Lung Cancer
Baehyun Shin
Senior Scientist
UCB
Track A - Day 1 AM
12:30 pm | In Vitro Neuromuscular Junction Models to Functionally Dissect Anti-AChR Pathogenic Mechanism in Myasthenia Gravis
Bärbel Rohrer
Professor
Medical University of South Carolina
Track A - Day 1 AM
12:00 pm | Complement Inhibitor for the Treatment of Age-related Macular Degeneration: Target, Location of Delivery & Timing?
Cynthia A. Lemere
Associate Professor of Neurology
Brigham & Women’s Hospital & Harvard Medical School
Daniel E. Benjamin
Chief Executive Officer
Cascade Biotechnology Inc.
Day Two
Thursday, September 29 2022
3:00 pm | Targeted Delivery Platform of sC3, a Complement Depleting Protein, Using Viral Delivery, Conjugate Guidance, & Localized Application Modalities
David Heja
Senior Scientist
eGenesis
Day Two
Thursday, September 29 2022
12:30 pm | Long-Term Graft Survival Achieved in NHP Recipients of Life- Sustaining, Endogenous Retrovirus-Free, Human-Compatible (Huco™) Porcine Renal Xenografts
Dorothy Schafer
Associate Professor of Neurobiology
UMass Chan Medical School
Edward F. Patz, Jr
CEO & James and Alice Chen Distinguished Professor of Radiology, Pharmacology & Cancer Biology
Grid Therapeutics, Duke University School of Medicine
Day Two
Thursday, September 29 2022
12:00 pm | Complement as a Natural Adjuvant to Promote Anti-Tumor Immunity in Cancer Therapy
Ellen Cahir-McFarland
Senior Vice President, Research
Annexon Biosciences
Track A - Day 1 PM
2:00 pm | Stop the Start: The Effect of Anti-C1q Inhibitors on Neurodegeneration
Emma Persson
Scientist, Clinical
argenx BV
Track B - Day 1 AM
12:20 pm | Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of ARGX-117, a Therapeutic Antibody Targeting Complement Factor 2
Frederick Beddingfield
Chief Executive Officer
Kira Pharma
Day One
Wednesday, September 28 2022
8:40 am | Complement Industry Leaders’ Chat - 2021/22 in Review & Looking Ahead
Day Two
Thursday, September 29 2022
9:00 am | To Be Announced
Gerry Cox
Interim Chief Medical Officer, Chief Development Strategist
CANbridge Pharmaceuticals
Track B - Day 1 AM
11:40 am | A Phase 1 Study of CAN106: A Novel, Long-Acting, Anti-C5 Monoclonal Antibody in Development for Complement-Mediated Diseases
Jeffry B. Lawrence
Industry Expert
Formerly at Solid Biosciences
Day One
Wednesday, September 28 2022
9:50 am | Panel Discussion: Defining the Therapeutic Windows of Drugs to Ensure Patient Safety Whilst Maintaining Drug Efficacy
9:20 am | Complement Inhibitory Drugs: Dose Selection & Schedule for Different Indications Based Upon Disease Mechanism, Pharmacokinetics & Pharmacodynamics
Karthik Viswanathan
Executive Director, Research
Visterra, Inc.
Track A - Day 1 PM
3:00 pm | Precision Antibody-Based Therapeutics for Complement Regulation
Keith Wilcoxen
Senior Vice President, Global Research
Zenas BioPharma
Day Two
Thursday, September 29 2022
3:30 pm | Opportunities for Complement Therapy in China
Maciej Markiewski
Professor
Texas Tech University Health Sciences Center
Day Two
Thursday, September 29 2022
10:00 am | Finding Optimal Targets for Complement-Based Cancer Therapy
Madhumita Das
Director, Immunology Discovery
Apellis Pharmaceuticals
Day One
Wednesday, September 28 2022
8:40 am | Complement Industry Leaders’ Chat - 2021/22 in Review & Looking Ahead
Day Two
Thursday, September 29 2022
11:30 am | Expanding Horizons in Cancer Therapeutics Targeting the Complement Pathway
Martin J. Schmidt
Chief Scientific Officer
Kypha
Track A - Day 1 PM 2
5:00 pm | Complement Biomarkers, the Utility of Complement Assays & Evaluating the Best Methods to Accurately Quantify Complement Activation
Martin Kolev
Associate Director Complement Science
Apellis Pharmaceuticals
Day Two
Thursday, September 29 2022
9:30 am | Inside-Out of Complement in Cancer Immunotherapy
Michael Schwenkert
Chief Technology Officer
Svar
Day One
Wednesday, September 28 2022
10:20 am | Importance of Complement Assays in Drug Development
Michael Storek
Head of Complement Cluster
Sanofi
Day One
Wednesday, September 28 2022
9:50 am | Panel Discussion: Defining the Therapeutic Windows of Drugs to Ensure Patient Safety Whilst Maintaining Drug Efficacy
8:40 am | Complement Industry Leaders’ Chat - 2021/22 in Review & Looking Ahead
8:30 am | Chair’s Opening Remarks
Michelle Elvington
Scientific Director - Complement & Clinical Development
Kypha
Day One
Wednesday, September 28 2022
9:10 am | Delivering clinically actionable complement diagnostics
Neel Krishna
Chief Scientific Officer
ReAlta Life Sciences
Track B - Day 1 AM
11:30 am | RLS-0071: Dual Target Inhibition in Support of Hypoxic Ischemic Encephalopathy
Nirmal K. Banda
Professor
University of Colorado Anschutz Medical Campus
Track A - Day 1 AM
11:30 am | Therapeutic Targeting C5AR1 to Diagnosing & Preventing Early Rheumatoid Arthritis as a New Pathway to Precision Medicine
Petra Duda
Head of Development – Zilucoplan
UCB
Track B - Day 1 PM
3:00 pm | Phase 3 Data in Generalized Myasthenia Gravis
Renfeng Guo
Chief Science Officer
InflaRx N.V.
Track B - Day 1 PM
2:00 pm | Treatment of Critically Ill COVID-19 Patients with Vilobelimab, a First-in-Class Anti-C5a Antibody
Richard Lee
Chief Medical Officer
Kira Pharma
Track B - Day 1 PM 2
4:31 pm | How Do You Manage Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibitors?
Ruchi Gupta
Vice President, Head of R&D
Pendulum Therapeutics
Day One
Wednesday, September 28 2022
9:50 am | Panel Discussion: Defining the Therapeutic Windows of Drugs to Ensure Patient Safety Whilst Maintaining Drug Efficacy
Day Two
Thursday, September 29 2022
8:50 am | Chair’s Opening Remarks
Stefan Wawersik
Vice President of Research
Q32 Bio Inc.
Day Two
Thursday, September 29 2022
2:30 pm | Developing Locally Targeted Complement Therapeutics
Stephen Poor
Director External Opportunities & Translational Biomarkers
Novartis Institutes for Biomedical Research
Track B - Day 1 PM
2:30 pm | An Update & Analysis of the Macular Degeneration Complement Landscape
Thomas J. Schall
President, Chief Executive Officer & Chairman of the Board
ChemoCentryx
Day One
Wednesday, September 28 2022
4:00 pm | Success Stories & Lessons Learned: TAVNEOS (Avacopan) – an Oral Inhibitor of the Complement C5a Receptor for the Treatment of ANCAAssociated Vasculitis
Yamini Bynagari
VP Clinical Research, Lead Scientist, Cell & Biochemical Assay Development
Machaon Diagnostics